Crescendo Biologics is a biopharmaceutical company developing potent, multi-functional Humabody® therapeutics in Oncology with a proprietary pipeline focus on CB307, a unique targeted T-cell engager.

Located in Cambridge, UK, we are backed by blue-chip investors including SOFINNOVA PARTNERS, ANDERA PARTNERS, IP GROUP PLC, TAKEDA, QUAN CAPITAL, ASTELLAS VENTURE MANAGEMENT, EMBL VENTURES and BABRAHAM INSTITUTE ENTERPRISE.